First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Ascendis Pharma presented Week 52 data from the open-label sentinel cohort of the Phase 2 reACHin trial showing once-weekly TransCon CNP (navepegritide) stabilized or improved foramen magnum stenosis in all seven infants with achondroplasia treated, with no decompression surgeries during the period. Treatment also drove linear growth gains, with a mean +0.42 change in ACH-specific supine length Z-score and annualized growth velocity of 9.9 cm/year, and the drug was generally well tolerated with no injection site reactions, deaths, or treatment-related adverse events over 52 weeks.
Key figures
- Drug Name
- TransCon CNP (navepegritide)
- Phase Of Trial
- Phase 2
- Afms outcome
- stable or improved in all children between baseline and Week 52
- Dose ug kg week
- 100
- Mean age months
- 11.7
- Sentinel cohort n
- 7
- Planned enrollment
- at least 66 infants aged 0 to <2 years
- Ema decision timing
- Q4 2026
- Yuvowel us approval
- February 2026, ages 2 and older
- Length zscore change
- 0.42
- Decompression surgeries
- 0
- Treatment duration weeks
- 52
- Achondroplasia prevalence worldwide
- more than 250,000 people
- Annualized growth velocity cm per year
- 9.9
- Foramen magnum sagittal diameter change mm
- 3.15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.